Specific biomarkers recently discovered by genomic analyses of glioma include O6-methylguanine-DNA methyltransferase methylation (MGMT), isocitrate dehydrogenase (IDH1) mutation, and a glioma cytosine-phosphate-guanine island methylator phenotype, all indicating improved patient survival (Ostrom et al., 2014[45]). Here, MGMT is linked to central nervous system cancer.